Long awaited results indicate a statistically significant difference in BIMF scores at day 45 (postpartum); women on Zuranolone were functioning better than those on placebo (on average):

“In addition to assessing clinician-rated measures of depression, anxiety, and global function, the patient-reported BIMF scores were assessed for maternal function. Numerically
greater increases in BIMF scores were observed for zuranolone vs placebo at all time points, with statistical significance at day 45 (least-squares means difference, 7.2; 95% CI, 1.3-13.0; P = .02) (eTable 9 in Supplement 2).”

For full results:  https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2781385.